

MACROMOLECULAR PLATINUM-BASED ANTICANCER AGENTS

Kayembe Jacques Diainabo

A thesis submitted to the faculty of Science, University of the Witwatersrand,
in fulfillment of the degree of Doctor of Philosophy in Science

Johannesburg, 2012

Declaration

I declare that this thesis is my own, unaided work. It is being submitted for the degree of Doctor of Philosophy of Science in the University of the Witwatersrand, Johannesburg. South Africa. It has not been submitted before for any degree or examination in any other University.

Kayembe Jacques Diainabo

_____ day of _____

ABSTRACT

Platinum is nowadays one of the best and widely used antitumor agents in cancer chemotherapy. The numerous performances reported by many previous researchers for this metal in the fight against several malignancies led to the synthesis of many platinum complexes. However, the clinical responses related to these complexes led to the development of non-platinum compounds with metal ions which exhibit antitumor activity. Ferrocene is one of them, owing the high consideration *inter alia* to its environmental oxidoreductive behavior. Methotrexate is another clinically used anticancer drug worthy to be mentioned. With a structure very close to that of folic acid, differing from it by an amine function and a methyl group, respectively, instead of an hydrogen and an hydroxyl group on the folate, methotrexate has been considered as an antagonist of folic acid by its mechanism of action in the biological environment. It has, together with platinum and non-platinum complexes, shown notorious side-effects by fighting both normal and abnormal cells despite their antineoplastic potency. This is the reason why a drug delivery system is considered as a tool to improve metal complexes and other drugs selectivity for cancer cells. The strategy of enhancing the potency of non-polymeric chemically, physically, or biologically active compounds through the expediency of binding such compounds to a polymeric carrier has revolutioned numerous technologies. In the present thesis is demonstrated the synthesis of several water-soluble macromolecular drug carriers intended for biomedical applications, and the anchoring of platinum to ferrocene-containing antineoplastic agents on one side, then to methotrexate-containing antineoplastic agents on the other side, resulting in a co-conjugate or a conjugate bearing two different drugs on a single carrier. This multidrug anchoring offers the advantage to exploit the potency of two different drugs on a single polymeric structure, each drug having its own pharmacokinetic path. Platinum is the common drug, while ferrocene and

methotrexate are the various co-drugs. This order of having the platinum imparted to the polymeric carrier after the two drugs above mentioned were adopted in obedience to the strategy of having the most synthetically demanding drug incorporated in the carrier before the least one. Anchoring of the three drugs to polymeric structures was achieved in aqueous environment. Methotrexate (MTX) and ferrocene (Fc) binding were achieved *via* HBTU as coupling agent. In all cases, more or less, but very close to, 100% drug loading could be achieved under careful control of experimental conditions. The water-soluble polymeric carriers used are copolyaspartamides, prepared by an aminolytic ring-opening process of polysuccinimide, and copoly(amidoamines) obtained by Michael polyaddition of methylenebisacrylamide (MBA). These polymers were designed to bear amine, hydroxyl or carboxylic acid functional groups in their structure, either as part of the main chain or side chain. The functional groups herein mentioned are important for the coupling of the chemically modified drug species. Exploratory *in-vitro* biological studies are discussed, as the co-conjugation of the metallic antineoplastic drug, ferrocene and the antifolate methotrexate, each with the metallic drug platinum, is performed. The results of these preliminary tests show that polymer-drug conjugates and co-conjugates can play a role in future cancer therapy.

DEDICATION

I dedicate this thesis to: my wife Lubuya Françoise Mwepu; my children Kalonji Henoc Mbombo Diainabo, Mwanza Grandie Diainabo, Mwadi Joyce Diainabo and Kapiamba Elie Diainabo; my mother Mwanza Tshibaya; my brothers Kabala Placide Jadika, Kapiamba ToTo, Mpunga Pierrot, Kalonji Timothée Mbombo and Tshibangu Jules; my sister Ntumba Therese and to all my family in law.

ACKNOWLEDGMENTS

I would like to thank the God of Israel, my God and savior for having led me up to so far in my studies.

I would also like to thank my supervisor Professor E. W. Neuse, for his patience, commitment, helpfulness, guidance, encouragement and support throughout the period of this study, as well as Professor Robyn Van Zyl for co-supervising this work and for her help during the biological test of our samples.

My thanks go also to Mr. Richard Mampa for his kindness during the NMR processings.

I am grateful to the research office of Wits University for the support with the Mellon scholarship.

I thank my colleague Hembe Elie Mukaya for his collaboration during our studies.

I don't forget the good advices and wishes of my brothers in Christ Mbuyu G. Ntunka and Emmanuel Nshingabigwi.

CONTENTS

LIST OF FIGURES.....	xii
LIST OF SCHEMES.....	xiii
LIST OF TABLES.....	xv
LIST OF ABBREVIATIONS.....	xix

CHAPTER 1- INTRODUCTION

1.1 Cancer problem.....	1
1.2 Cancer and HIV-AIDS.....	1
1.3 Objectives of the study.....	3

CHAPTER 2- OVERVIEW OF CANCER TREATMENT MODALITIES

2.1 Surgery.....	5
2.1.1 Curative surgery.....	6
2.1.2 Cytoreductive and palliative surgery.....	6
2.1.3 Diagnostic and staging surgery.....	6
2.1.4 Prophylactic surgery.....	6

2.1.5 Supportive and restorative surgery.....	7
2.2 Radiation therapy.....	7
2.3 Chemotherapy.....	8
2.3.1 History of cancer chemotherapy.....	9
2.3.2 Principles of cancer chemotherapy.....	10
2.3.3 Treatment schemes of cancer by chemotherapy.....	11
2.3.4 Types of anticancer agents.....	12
2.3.4.1 Alkylating drugs.....	14
2.3.4.2 Antibiotics.....	22
2.3.4.3 Antimetabolites.....	25
2.3.4.4 Other chemotherapeutic drugs.....	35
2.4 Combination therapy.....	50
2.5 Immunotherapy.....	50
2.6 Antiangiogenesis therapy.....	51
2.7 Photodynamic therapy.....	51
2.8 Gene therapy.....	52
 CHAPTER 3- MACROMOLECULAR CARRIERS AND	
POLYMERIC ANTICANCER DRUG	
CONJUGATES	
3.1 Background and literature review.....	53

3.2 Polymers as drug carriers.....	53
3.2.1 Requirements for polymeric drug carriers.....	55
3.2.1.1 <i>Hydrosolubility</i>	55
3.2.1.2 <i>Degradability</i>	55
3.2.1.3 <i>Immunogenicity</i>	57
3.2.1.4 <i>Drug anchoring</i>	58
3.2.2 Natural polymers as drug carriers.....	59
3.2.3 Synthetic polymers as drug carriers.....	60
3.2.3.1 <i>Aminoacid polymers and copolymers</i>	61
3.2.3.2 <i>Poly (amidoamines)</i>	62
3.2.4 Advantages of drug carriers and their mechanism of Action.....	64
3.2.5 Polymer-drug conjugation.....	68
3.2.5.1 <i>Polymer-folic acid anchoring</i>	68
3.2.5.2 <i>Polymer-MTX conjugation</i>	69
3.2.5.3 <i>Polymer-ferrocene conjugation</i>	69
3.2.5.4 <i>Polymer-platinum conjugation</i>	70
3.2.6 Multidrug conjugation.....	72

CHAPTER 4- RESULTS AND DISCUSSION

4.1 Polymeric Drug Carriers.....	74
----------------------------------	----

4.1.1 Introduction.....	74
4.1.2 Polyaspartamide carriers.....	78
4.1.2.1 Synthesis of polysuccinimide (PSI).....	78
4.1.2.2 Preparation of homopoly(α , β -DL-aspartamide).....	78
4.1.2.3 Preparation of copolyaspartamides.....	80
4.1.3 Polyamidoamine carriers.....	103
4.2 Polymer-drug conjugation.....	122
4.2.1 Polymer-ferrocene conjugates.....	122
4.2.2 Polymer-methotrexate conjugates.....	134
4.2.2.1 Copolyaspartamide-based MTX conjugates.....	135
4.2.2.2 Polyamidoamine-based MTX conjugates.....	141
4.2.3 Polymer-platinum co-conjugates.....	147
4.2.3.1 Synthesis of Fc/Pt co-conjugates.....	151
4.2.3.1.1 Preparation of copolyaspartamide- Fc/Pt co-conjugates.....	154
4.2.3.1.2 Preparation of copolyamidoamine- Fc/Pt co-conjugates.....	157
4.2.3.2 Synthesis of MTX/Pt co-conjugates.....	160
4.2.3.2.1 Preparation of copolyaspartamide- MTX/Pt co-conjugates.....	163
4.2.3.2.2 Preparation of copolyamidoamine- MTX/Pt co-conjugates.....	166
4.3 Cell culture testing.....	170

CHAPTER 5- EXPERIMENTAL

5. 1 General procedures.....	175
5. 2 Reagents, solvents and monomeric reactants.....	176
5.3 Experimental Procedures.....	177
5.3.1 Preparation of polymeric carriers.....	177
5. 3. 2 Preparation of conjugates.....	207
5. 3. 3 Preparation of platinum co-conjugates.....	223

CHAPTER 6- CONCLUSION AND FUTURE WORK.....235**REFERENCES..... 240**

LIST OF FIGURES

Figure 2.1: Cell cycle phases.....	8
Figure 2.2: Structures of two DNA alkylating agents.....	16
Figure 2.3: Structure of methotrexate.....	26
Figure 2.4: Structure of folic acid.....	29
Figure 2.5: Fate of folic acid in the biological environment.....	30
Figure 2.6: Structures of purine analog antimetabolites.....	33
Figure 2.7: Structures of pyrimidine antimetabolites.....	35
Figure 2.8: Exemplifying platinum coordination complexes showing anticancer activity.....	37
Figure 2.9: Interstrand and intrastrand crosslinking of DNA with cisplatin....	40
Figure 2.10: Second generation platinum drugs.....	43
Figure 2.11: Behavior of ferrocene in the physiologic environment.....	49
Figure 3.1: Uptake of macromolecules by pinocytosis.....	66
Figure 3.2: The EPR effect.....	67
Figure 4.1: Structure of polyamide carrier.....	75
Figure 4.2: Structures of aliphatic tertiary amine, cyclic and aromatic solubilizing groups.....	83
Figure 4.3: Structures of primary amines yielding the spacer R_2	84
Figure 4.4: Structures of 1,2 dihydroxylated monoamine monomers.....	84

Figure 4.5: Model of platinum conjugate via dihydroxylato-chelation.....	149
---	-----

LIST OF SCHEMES

Scheme 2.1: The aqueous chemistry of <i>cisplatin</i>	39
Scheme 2.4: Reaction of ferrocene in the biological environment.....	46
Scheme 2.5: Reaction of ferrocene in the biological environment.....	46
Scheme 2.6: Reaction of ferrocene in the biological environment.....	46
Scheme 2.7: Reaction of ferrocene in the biological environment.....	47
Scheme 4.1: Synthesis of polysuccinimide.....	79
Scheme 4.2: Synthesis of poly- α,β -DL-aspartamide.....	80
Scheme 4.3: Preparation of copolyaspartamides.....	82
Scheme 4.4: Synthesis of copolyaspartamides containing 3-aminopropyl-1,2-Diol.....	85
Scheme 4.5: Copolyaspartamides containing noradrenaline.....	94
Scheme 4.6: Synthesis of polyamidoamine carriers containing APD.....	104
Scheme 4.7: Synthesis of polyamidoamines bearing D,L-aspartic acid.....	113
Scheme 4.8: Coupling of copolyaspartamide carriers with ferrocene.....	124
Scheme 4.9: Coupling of copolyamidoamine carriers with ferrocene.....	125
Scheme 4.10: Synthesis of copolyaspartamide-MTX conjugates.....	136
Scheme 4.11: Synthesis of copolyamidoamine-MTX conjugates.....	142
Scheme 4.12: Synthesis of DACH-Pt as platination agent.....	150

Scheme 4.13: Synthesis of copolyaspartamide-based Fc/Pt co-conjugates.....	152
Scheme 4.14: Synthesis of copolyamidoamine-based Fc/Pt co-conjugates.....	153
Scheme 4.15: Preparation of copolyaspartamide-based MTX/Pt co-conjugates.....	161
Scheme 4.16: Preparation of copolyamidoamine-based MTX/Pt co-Conjugates.....	162

LIST OF TABLES

Table 4.1: Copolyaspartamides with APD as platinum binding site and aliphatic solubilizing groups.....	86
Table 4.2: Summary of preparative data for copolyaspartamide carriers with APD as platinum binding site and aliphatic solubilising groups...	88
Table 4.3: ^1H NMR and viscometric results for copolyaspartamides with APD for platinum binding and aliphatic solubilizing groups.....	89
Table 4.4: composition of copolyaspartamides bearing APD as platinum binding site with cyclic and aromatic solubilizing groups.....	90
Table 4.5: Summary of preparative data for copolyaspartamide carriers with APD as platinum binding site bearing cyclic and aromatic solubilising groups.....	92
Table 4.6: ^1H NMR and viscometric results for copolyaspartamides with APD for platinum binding bearing cyclic and aromatic solubilizing groups.....	93
Table 4.7: copolyaspartamides with Noradrenaline as platinum binding site and aliphatic solubilizing groups.....	95
Table 4.8: Summary of preparative data for copolyaspartamide carriers with Noradrenaline as platinum binding site bearing aliphatic solubilising groups.....	97
Table 4.9: ^1H NMR and viscometric results for copolyaspartamides with APD for platinum binding and aliphatic solubilizing groups.....	98
Table 4.10: copolyaspartamides with noradrenaline for platinum binding, bearing cyclic and aromatic solubilizing groups.....	99
Table 4.11: Summary of preparative data for copolyaspartamide carriers with noradrenaline as platinum binding site bearing cyclic and	

aromatic solubilising groups.....	101
Table 4.12: ^1H NMR and viscometric results for copolyaspartamides with noradrenaline for platinum binding, bearing cyclic and aromaticsolubilizing groups.....	102
Table 4.13: Composition of polyamidoamines carriers bearing APD and aliphatic solubilizing groups.....	105
Table 4.14: Summary of preparative data for polyamidoamine carriers with APD as platinum binding site bearing aliphatic solubilising groups.....	107
Table 4.15: ^1H NMR and viscometric results for polyamidoamine carriers with APD for platinum binding and aliphatic solubilizing groups.....	108
Table 4.16: composition of polyamidoamine carriers bearing APD with cyclic and aromatic solubilizing groups.....	109
Table 4.17: Summary of preparative data for polyamidoamine carriers with APD as platinum binding site bearing cyclic and aromatic solubilising groups.....	111
Table 4.18: ^1H NMR and viscometric results for polyamidoamines with APD for platinum binding bearing cyclic and aromaticsolubilizing groups.....	112
Table 4.19: Polyamidoamines with D, L-Aspartic acid, bearing aliphatic solubilizing groups.....	114
Table 4.20: Summary of preparative data for polyamidoamine carriers with D, L-aspartic acid as platinum binding site bearing aliphatic solubilizing groups.....	116
Table 4.21: ^1H NMR and viscosimetric results for polyamidoamines with aspartic acid for platinum binding bearing aliphatic solubilizing groups.....	117
Table 4.22: Polyamidoamines with Aspartic acid, bearing cyclic and aromatic solubilizing groups.....	118
Table 4.23: Summary of preparative data for Copolyaspartamide carriers with	

aspartic acid as platinum binding site, bearing cyclic and aromatic solubilising groups.....	120
Table 4.24: ^1H NMR and viscometric results for Copolyaspartamides with APD for platinum binding and aliphatic solubilizing groups.....	121
Table 4.25: Composition of Copolyaspartamide-ferrocene conjugates prepared by HBTU-mediated coupling method.....	126
Table 4.26: Experimental data for the synthesis of Copolyaspartamide-based ferrocene conjugates.....	127
Table 4.27: ^1H NMR and viscometric data for Copolyaspartamide-based ferrocene conjugates.....	128
Table 4.28: Summary of analytical data for Copolyaspartamide-based ferrocene conjugates.....	129
Table 4.29: Composition of Polyamidoamine-ferrocene conjugates prepared by HBTU-mediated coupling method.....	130
Table 4.30: Experimental data for the synthesis of Polyamidoamine-based ferrocene conjugates.....	131
Table 4.31: ^1H NMR and viscometric data for Polyamidoamine-based ferrocene conjugates.....	132
Table 4.32: Summary of analytical data for Polyamidoamine-based ferrocene conjugates.....	133
Table 4.33: Composition of Copolyaspartamide-MTX conjugates prepared by HBTU-mediated coupling method.....	137
Table 4.34: Experimental data for the synthesis of Copolyaspartamide-based MTX conjugates.....	138
Table 4.35: ^1H NMR and viscometric data for Copolyaspartamide-based MTX Conjugates.....	139
Table 4.36: Summary of analytical data for Copolyaspartamide-based MTX Conjugates.....	140
Table 4.37: Composition of Polyamidoamine-MTX conjugates prepared by HBTU-mediated coupling method.....	143

Table 4.38: Experimental data for the synthesis of Polyamidoamine-based MTX conjugates.....	144
Table 4.39: ^1H NMR and viscometric data for Polyamidoamine-based MTX Conjugates.....	145
Table 4.40: Summary of analytical data for Polyamidoamine-based MTX Conjugates.....	146
Table 4.41: Experimental data for the synthesis of copolyaspartamide-based Fc/Pt co-conjugates.....	155
Table 4.42: ^1H NMR, viscosities and metal content of copoyaspartamide-based Fc/Pt co-conjugates.....	156
Table 4.43: Experimental data for the synthesis of polyamidoamine-based Fc/Pt co-conjugates.....	158
Table 4.44: ^1H NMR, viscometric data and metal content for polyamidoamine-based Fc/Pt co-conjugates.....	159
Table 4.45: Experimental data for the synthesis of copolyaspartamide-based MTX/Pt co-conjugates.....	164
Table 4.46: ^1H NMR, viscometric data and drug content for copolyaspartamide-based MTX/Pt conjugates.....	165
Table 4.47: Compositions, experimental data and viscosities of polyamidoamine-based MTX/Pt co-conjugates.....	167
Table 4.48: ^1H NMR, viscometric data and drug contents for copolyamidoamine-based MTX/Pt co-conjugates.....	168
Table 4.49: Antiproliferative activities of free drugs, copolyaspartamide and copolyamidoamine homo and co-conjugates.....	172

LIST OF ABBREVIATIONS

AEE	2- (2-aminoethoxy) ethanol
AEM	3- (2- aminoethyl) morpholine
APD	3- amino 1, 2 propanediol
APM	4- (3- aminopropyl) morpholine
Aspac	Aspartic acid
CoPAs	Copopyaspartamide
DCC	Dicyclohexylcarbodiimide
DEEA	Diethylaminoethylamine
API	Aminopropyl imidazole
DEP	Diethylaminopropylamine
DET	Diethylenetriamine
DMEA	Dimethylaminoethylamine
DMF	Dimethylformamide
DMSO	Dimethylsulfoxyde

EA	Ethanolamine
EDA	Ethylenediamine
EDDA	2, 2' – (ethylenedioxy) diethylamine
EPR	Enhanced permeability retention
FA	Folic acid
FAO	Food and agricultural organization
FRC	Folate reduced carrier
HBTU	2- (1H-benzotriazol- 1 – yl) – 1, 1, 3, 3 – Tetramethyluroniumhexafluorophosphate
HMP	Hexamethylphosphoramide
HSU	N- hydroxysuccinimide
Inh	Inherent
MBA	Methylenebisacrylamide
MDR	Multi- drug resistance
MTX	Methotrexate
NMP	N- Methylpyrrolidone
NMR	Nuclear magnetic resonance
Copaa	copoly (amidoamine)
PAAs	Poly(amidoamines)
PABA	Paraaminobenzoic acid

PAs	Polyaspartamide
PASA	Paraminosalicylic acid
PDA	1, 3 –propylenediamine
PEG	Poly (ethyleneglycol)
PSI	Polysuccinimide
RNA	Ribonucleic acid
RT	Room temperature
TEA	Triethylamine
TRIA	4, 7, 10 – trioxa- 1, 13 - tridecanediamine

